IDH1 and glioblastoma: The results showing in ROC curves that the AUCs of the risk signature for 1‐, 3‐ and 5‐year survival prediction were larger than those of IDH1, MGMT promoter and CIMP status indicated the risk signature was more accurate for predicting the survival of GBM patients.